Poseida Therapeutics Q2 EPS $(0.32) Up From $(0.69) YoY, Sales $20.01M Up From $2.70M YoY
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics reported Q2 earnings with losses of $(0.32) per share, a 53.62% increase YoY. The company also reported $20.01M in sales, a 641.22% increase YoY.
August 08, 2023 | 10:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics reported improved Q2 earnings with reduced losses and significantly increased sales YoY.
Poseida Therapeutics reported a significant improvement in their Q2 earnings with a 53.62% reduction in losses per share and a 641.22% increase in sales compared to the same period last year. This indicates a positive financial performance which could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100